CA2607444C - Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells - Google Patents

Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells Download PDF

Info

Publication number
CA2607444C
CA2607444C CA2607444A CA2607444A CA2607444C CA 2607444 C CA2607444 C CA 2607444C CA 2607444 A CA2607444 A CA 2607444A CA 2607444 A CA2607444 A CA 2607444A CA 2607444 C CA2607444 C CA 2607444C
Authority
CA
Canada
Prior art keywords
antibody
antibodies
cells
fra
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2607444A
Other languages
English (en)
French (fr)
Other versions
CA2607444A1 (en
Inventor
Luigi Grasso
Nicholas C. Nicolaides
Phillip M. Sass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of CA2607444A1 publication Critical patent/CA2607444A1/en
Application granted granted Critical
Publication of CA2607444C publication Critical patent/CA2607444C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2607444A 2005-04-22 2006-04-24 Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells Active CA2607444C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67418505P 2005-04-22 2005-04-22
US60/674,185 2005-04-22
PCT/US2006/016004 WO2006116592A2 (en) 2005-04-22 2006-04-24 Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

Publications (2)

Publication Number Publication Date
CA2607444A1 CA2607444A1 (en) 2006-11-02
CA2607444C true CA2607444C (en) 2015-03-10

Family

ID=37215502

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2607444A Active CA2607444C (en) 2005-04-22 2006-04-24 Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

Country Status (6)

Country Link
US (5) US20060239910A1 (enExample)
EP (2) EP1879922A2 (enExample)
JP (2) JP2009521206A (enExample)
AU (1) AU2006241099B2 (enExample)
CA (1) CA2607444C (enExample)
WO (1) WO2006116592A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004249673A1 (en) * 2003-05-23 2004-12-29 Morphotek, Inc. Anti alpha - folate - receptor - tetramer antibodies
WO2005011735A1 (en) * 2003-07-29 2005-02-10 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
EP2316857A1 (en) 2004-02-12 2011-05-04 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
JP4949373B2 (ja) * 2005-03-10 2012-06-06 モルフォテック、インク． 抗メソテリン抗体
EP1879922A2 (en) 2005-04-22 2008-01-23 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
AU2009205706B2 (en) 2008-01-15 2015-03-19 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
CA2711938C (en) 2008-01-15 2019-11-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by cd47
AU2014203172B2 (en) * 2010-02-24 2016-03-10 Immunogen, Inc. Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
KR20170085143A (ko) * 2010-02-24 2017-07-21 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
LT3789038T (lt) 2010-05-14 2022-12-12 The Board Of Trustees Of The Leland Stanford Junior University Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47
US20120164137A1 (en) * 2010-10-20 2012-06-28 Morphotek, Inc. Anti-folate receptor alpha antibody glycoforms
RU2764592C2 (ru) * 2010-11-05 2022-01-18 Эйсэй Инк. Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа
EP2665521A4 (en) * 2011-01-18 2014-09-03 Univ Pennsylvania COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
CA2830628A1 (en) 2011-03-18 2012-09-27 Kagoshima University Composition for treatment and diagnosis of pancreatic cancer
CA3182262A1 (en) 2011-04-01 2012-10-04 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
JP6220333B2 (ja) 2011-07-15 2017-10-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗葉酸受容体アルファ抗体およびその使用
WO2014036495A2 (en) * 2012-08-31 2014-03-06 Immunogen Inc. Diagnostic assays and kits for detection of folate receptor 1
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014087863A1 (ja) * 2012-12-07 2014-06-12 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
WO2014205342A2 (en) 2013-06-20 2014-12-24 Morphotek, Inc. Methods for treatment of ovarian cancer
RS62240B1 (sr) 2013-08-30 2021-09-30 Immunogen Inc Antitela i testovi za detekciju folatnog receptora 1
SG11201704056XA (en) 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
HRP20201156T1 (hr) 2014-11-20 2020-11-13 F. Hoffmann - La Roche Ag Zajednički laki lanci i postupci primjene
CA2960929A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules against folr1 and cd3
BR112017022320A2 (pt) 2015-04-17 2018-07-24 Morphotek Inc métodos para tratamento de câncer de pulmão
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
CN108290948B (zh) 2015-09-21 2021-10-29 伊拉兹马斯大学医疗中心 抗-cd47抗体及使用方法
BR112020016469A2 (pt) 2018-03-13 2020-12-15 Phanes Therapeutics, Inc. Anticorpos do receptor anti-folato 1 e seus usos
KR102275930B1 (ko) 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7426661B2 (ja) * 2018-12-17 2024-02-02 株式会社カネカ 特定抗原特異的抗体を産生する細胞のスクリーニング方法
JP7585230B2 (ja) 2019-04-29 2024-11-18 イミュノジェン， インコーポレイテッド バイパラトピックＦＲ－α抗体及びイムノコンジュゲート
WO2024104431A1 (zh) * 2022-11-16 2024-05-23 迈威(上海)生物科技股份有限公司 一种靶向FRα的抗体或其抗原结合片段及其应用
US12378314B1 (en) * 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) * 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US4851332A (en) 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5006470A (en) * 1987-04-16 1991-04-09 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens of melanoma
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE171207T1 (de) * 1990-10-12 1998-10-15 Us Health Monoklonaler antikörper
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US6191268B1 (en) * 1993-12-17 2001-02-20 Dana-Farber Cancer Institute Compositions and methods relating to DNA mismatch repair genes
WO1995020678A1 (en) * 1994-01-27 1995-08-03 Human Genome Sciences, Inc. Human dna mismatch repair proteins
DE19513676A1 (de) * 1995-04-11 1996-10-17 Behringwerke Ag Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
ATE254931T1 (de) * 1996-01-05 2003-12-15 Us Gov Health & Human Serv Mesothelinantigen, verfahren und testsatz zur targetierung
CN1217750A (zh) 1996-05-04 1999-05-26 曾尼卡有限公司 抗cea的单克隆抗体,包括所述抗体的偶联物及其在adept系统中的治疗应用
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
US6146894A (en) 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
US6365410B1 (en) * 1999-05-19 2002-04-02 Genencor International, Inc. Directed evolution of microorganisms
WO2000073346A1 (en) 1999-05-27 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunoconjugates having high binding affinity
WO2003084469A2 (en) 2002-04-01 2003-10-16 Utah Ventures Ii, L.P. Tissue-specific endothelial membrane proteins
EP1345495B1 (en) 2000-11-07 2009-02-25 Morphotek Inc. Methods for generating genetically altered antibody-producing cell lines with improved antibody characteristics
US6808894B1 (en) * 2000-11-07 2004-10-26 Morphotek, Inc. Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics
CA2434926C (en) 2001-01-15 2014-04-01 Morphotek, Inc. Chemical inhibitors of mismatch repair
KR20040015234A (ko) * 2001-05-02 2004-02-18 펄듀 리서치 파운데이션 대식세포 매개된 질환의 치료와 진단
JP2005504517A (ja) 2001-05-18 2005-02-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＣＤ４４ｖ６特異的抗体
EP1258255A1 (en) 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EP1551988B1 (en) 2002-07-19 2010-11-24 Morphotek, Inc. Methods for generating enhanced antibody-producing cell lines with improved growth characteristics
AU2004249673A1 (en) * 2003-05-23 2004-12-29 Morphotek, Inc. Anti alpha - folate - receptor - tetramer antibodies
WO2005011735A1 (en) 2003-07-29 2005-02-10 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
US20050054056A1 (en) 2003-08-05 2005-03-10 Wolfgang Ebel Variant cell surface molecule associated with cancer
EP2316857A1 (en) * 2004-02-12 2011-05-04 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
JP2008515438A (ja) 2004-10-05 2008-05-15 ワイス 組換えタンパク質産生の改善方法および組成物
JP4949373B2 (ja) * 2005-03-10 2012-06-06 モルフォテック、インク． 抗メソテリン抗体
CA2602585A1 (en) * 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
EP1879922A2 (en) 2005-04-22 2008-01-23 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
WO2007038346A2 (en) * 2005-09-23 2007-04-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US20080015160A1 (en) * 2005-11-04 2008-01-17 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
CA2668197A1 (en) * 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
RU2523909C2 (ru) 2007-06-25 2014-07-27 Эндосайт, Инк. Конъюгаты, содержащие гидрофильные спейсеры линкеров
WO2009032974A2 (en) * 2007-09-06 2009-03-12 Tripath Imaging, Inc. Nucleic acid-based methods for the detection of ovarian cancer
GB0725077D0 (en) 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
US20120164137A1 (en) * 2010-10-20 2012-06-28 Morphotek, Inc. Anti-folate receptor alpha antibody glycoforms
RU2764592C2 (ru) * 2010-11-05 2022-01-18 Эйсэй Инк. Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа
JP6122948B2 (ja) * 2012-05-15 2017-04-26 モルフォテック， インコーポレイテッド 胃癌の治療のための方法
WO2014087863A1 (ja) * 2012-12-07 2014-06-12 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
WO2014205342A2 (en) * 2013-06-20 2014-12-24 Morphotek, Inc. Methods for treatment of ovarian cancer
BR112017022320A2 (pt) * 2015-04-17 2018-07-24 Morphotek Inc métodos para tratamento de câncer de pulmão
RS62108B1 (sr) * 2016-03-02 2021-08-31 Eisai R&D Man Co Ltd Antitelo-lek konjugati na bazi eribulina i postupci primene

Also Published As

Publication number Publication date
US20170073425A1 (en) 2017-03-16
US20120171200A1 (en) 2012-07-05
US20160058885A1 (en) 2016-03-03
EP1879922A2 (en) 2008-01-23
EP2172487A1 (en) 2010-04-07
WO2006116592A9 (en) 2007-03-22
WO2006116592A3 (en) 2007-04-19
CA2607444A1 (en) 2006-11-02
AU2006241099B2 (en) 2012-04-19
US10253106B2 (en) 2019-04-09
JP2009521206A (ja) 2009-06-04
US9144614B2 (en) 2015-09-29
US20090324594A1 (en) 2009-12-31
US9522195B2 (en) 2016-12-20
US8124083B2 (en) 2012-02-28
AU2006241099A1 (en) 2006-11-02
US20060239910A1 (en) 2006-10-26
JP2012100675A (ja) 2012-05-31
WO2006116592A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
US10253106B2 (en) Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP1861425B1 (en) Anti-mesothelin antibodies
US8389691B2 (en) Antibodies with immune effector activity and that internalize in endosialin-positive cells
AU2017239474B2 (en) Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
AU2012254877B2 (en) Anti-mesothelin antibodies
AU2012205242B2 (en) Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
AU2014202667A1 (en) Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

Legal Events

Date Code Title Description
EEER Examination request